Medincell SA (MEDCL) - Net Assets
Based on the latest financial reports, Medincell SA (MEDCL) has net assets worth €3.06 Million EUR (≈ $3.58 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€108.05 Million ≈ $126.33 Million USD) and total liabilities (€104.99 Million ≈ $122.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Medincell SA (MEDCL) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.06 Million |
| % of Total Assets | 2.84% |
| Annual Growth Rate | 8.75% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 45.39 |
Medincell SA - Net Assets Trend (2016–2026)
This chart illustrates how Medincell SA's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see MEDCL company net worth.
Annual Net Assets for Medincell SA (2016–2026)
The table below shows the annual net assets of Medincell SA from 2016 to 2026. Also explore Medincell SA equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | €3.06 Million ≈ $3.58 Million |
+118.72% |
| 2025-03-31 | €-16.37 Million ≈ $-19.13 Million |
+59.91% |
| 2024-03-31 | €-40.82 Million ≈ $-47.73 Million |
+3.48% |
| 2023-03-31 | €-42.29 Million ≈ $-49.45 Million |
-216.31% |
| 2022-03-31 | €-13.37 Million ≈ $-15.63 Million |
-249.97% |
| 2021-03-31 | €8.92 Million ≈ $10.42 Million |
+155.87% |
| 2020-03-31 | €-15.96 Million ≈ $-18.66 Million |
-355.61% |
| 2019-03-31 | €6.24 Million ≈ $7.30 Million |
+153.14% |
| 2018-03-31 | €-11.75 Million ≈ $-13.74 Million |
-413.51% |
| 2017-03-31 | €-2.29 Million ≈ $-2.67 Million |
-272.81% |
| 2016-03-31 | €1.32 Million ≈ $1.55 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medincell SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5130.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €359.00K | 11.72% |
| Other Comprehensive Income | €-11.45 Million | -373.56% |
| Other Components | €45.44 Million | 1482.96% |
| Total Equity | €3.06 Million | 100.00% |
Medincell SA Competitors by Market Cap
The table below lists competitors of Medincell SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Orient International Enterprise Ltd
SHG:600278
|
$790.78 Million |
|
Shenzhen Centralcon Investment Holding Co Ltd
SHE:000042
|
$790.93 Million |
|
Changzhou Youon Pubilic Bicycle System Co Ltd
SHG:603776
|
$791.28 Million |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
$791.34 Million |
|
Xiamen Guang Pu Electronics Co Ltd
SHE:300632
|
$790.44 Million |
|
Pexip Holding ASA
OL:PEXIP
|
$790.43 Million |
|
Dogus Otomotiv Servis ve Ticaret AS
IS:DOAS
|
$789.87 Million |
|
AXISCADES Technologies Limited
NSE:AXISCADES
|
$789.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medincell SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from -16,367,000 to 3,064,000, a change of 19,431,000.
- Net loss of 31,287,000 reduced equity.
- New share issuances of 45,510,000 increased equity.
- Other comprehensive income increased equity by 75,977,000.
- Other factors decreased equity by 70,769,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-31.29 Million | -1021.12% |
| Share Issuances | €45.51 Million | +1485.31% |
| Other Comprehensive Income | €75.98 Million | +2479.67% |
| Other Changes | €-70.77 Million | -2309.69% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Medincell SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 250.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 249.66x to 250.79x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-03-31 | €0.09 | €21.40 | x |
| 2017-03-31 | €-0.16 | €21.40 | x |
| 2018-03-31 | €-0.82 | €21.40 | x |
| 2019-03-31 | €0.36 | €21.40 | x |
| 2020-03-31 | €-0.79 | €21.40 | x |
| 2021-03-31 | €0.40 | €21.40 | x |
| 2022-03-31 | €-0.54 | €21.40 | x |
| 2023-03-31 | €-1.68 | €21.40 | x |
| 2024-03-31 | €-1.44 | €21.40 | x |
| 2025-03-31 | €-0.56 | €21.40 | x |
| 2026-03-31 | €0.09 | €21.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medincell SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1021.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -160.27%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 35.27x
- Recent ROE (-1021.12%) is below the historical average (-136.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 50.16% | 7.56% | 0.74x | 9.01x | €498.00K |
| 2017 | 0.00% | -41.73% | 0.37x | 0.00x | €-3.33 Million |
| 2018 | 0.00% | -148.66% | 0.25x | 0.00x | €-8.39 Million |
| 2019 | -315.35% | -1364.31% | 0.04x | 6.08x | €-20.31 Million |
| 2020 | 0.00% | -838.53% | 0.10x | 0.00x | €-22.32 Million |
| 2021 | -213.32% | -232.35% | 0.13x | 7.13x | €-19.91 Million |
| 2022 | 0.00% | -606.50% | 0.09x | 0.00x | €-23.47 Million |
| 2023 | 0.00% | -321.90% | 0.34x | 0.00x | €-27.78 Million |
| 2024 | 0.00% | -273.34% | 0.25x | 0.00x | €-20.96 Million |
| 2025 | 0.00% | -72.19% | 0.28x | 0.00x | €-16.80 Million |
| 2026 | -1021.12% | -160.27% | 0.18x | 35.27x | €-31.59 Million |
Industry Comparison
This section compares Medincell SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $28,644,502
- Average return on equity (ROE) among peers: -86.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medincell SA (MEDCL) | €3.06 Million | 50.16% | 34.27x | $790.73 Million |
| Abionyx Pharma SA (ABNX) | $7.42 Million | -59.27% | 0.81x | $68.88 Million |
| Abivax SA (ABVX) | $196.01 Million | -75.37% | 0.67x | $8.82 Billion |
| Adocia (ADOC) | $10.69 Million | -44.27% | 0.41x | $83.81 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $15.30 Million |
| Biophytis S.A. (ALBPS) | $5.71 Million | -587.66% | 5.36x | $2.38 Million |
| Cellectis (ALCLS) | $75.87 Million | -92.72% | 3.28x | $114.74 Million |
| Advicenne (ALDVI) | $-10.62 Million | 0.00% | 0.00x | $12.61 Million |
| Genoway (ALGEN) | $-1.57 Million | 0.00% | 0.00x | $31.09 Million |
| Integragen (ALINT) | $3.09 Million | -65.97% | 1.25x | $746.14K |
| Medesis Pharma SA (ALMDP) | $-1.06 Million | 0.00% | 0.00x | $1.80 Million |
About Medincell SA
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment … Read more